CYTK
Price
$34.12
Change
-$1.13 (-3.21%)
Updated
Aug 8 closing price
Capitalization
4.21B
82 days until earnings call
HUMA
Price
$2.48
Change
+$0.01 (+0.40%)
Updated
Aug 8 closing price
Capitalization
383.14M
10 days until earnings call
Interact to see
Advertisement

CYTK vs HUMA

Header iconCYTK vs HUMA Comparison
Open Charts CYTK vs HUMABanner chart's image
Cytokinetics
Price$34.12
Change-$1.13 (-3.21%)
Volume$2.1M
Capitalization4.21B
Humacyte
Price$2.48
Change+$0.01 (+0.40%)
Volume$10.02M
Capitalization383.14M
CYTK vs HUMA Comparison Chart in %
Loading...
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HUMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CYTK vs. HUMA commentary
Aug 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongBuy and HUMA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 10, 2025
Stock price -- (CYTK: $34.11 vs. HUMA: $2.48)
Brand notoriety: CYTK and HUMA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 153% vs. HUMA: 266%
Market capitalization -- CYTK: $4.21B vs. HUMA: $383.14M
CYTK [@Biotechnology] is valued at $4.21B. HUMA’s [@Biotechnology] market capitalization is $383.14M. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileHUMA’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • HUMA’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than HUMA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 5 TA indicator(s) are bullish while HUMA’s TA Score has 4 bullish TA indicator(s).

  • CYTK’s TA Score: 5 bullish, 5 bearish.
  • HUMA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CYTK is a better buy in the short-term than HUMA.

Price Growth

CYTK (@Biotechnology) experienced а -7.03% price change this week, while HUMA (@Biotechnology) price change was +8.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.25%. For the same industry, the average monthly price growth was +6.85%, and the average quarterly price growth was +13.24%.

Reported Earning Dates

CYTK is expected to report earnings on Oct 30, 2025.

HUMA is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+0.25% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($4.21B) has a higher market cap than HUMA($383M). CYTK YTD gains are higher at: -27.487 vs. HUMA (-50.891). HUMA has higher annual earnings (EBITDA): -59.97M vs. CYTK (-513.62M). CYTK has more cash in the bank: 938M vs. HUMA (62.8M). HUMA has less debt than CYTK: HUMA (15.8M) vs CYTK (791M). CYTK has higher revenues than HUMA: CYTK (19.2M) vs HUMA (517K).
CYTKHUMACYTK / HUMA
Capitalization4.21B383M1,099%
EBITDA-513.62M-59.97M856%
Gain YTD-27.487-50.89154%
P/E RatioN/AN/A-
Revenue19.2M517K3,714%
Total Cash938M62.8M1,494%
Total Debt791M15.8M5,006%
FUNDAMENTALS RATINGS
CYTK: Fundamental Ratings
CYTK
OUTLOOK RATING
1..100
69
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
PROFIT vs RISK RATING
1..100
91
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
60
P/E GROWTH RATING
1..100
1
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CYTKHUMA
RSI
ODDS (%)
Bearish Trend 2 days ago
64%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 24 days ago
80%
Declines
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
HUMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
STITX7.54N/A
N/A
Virtus SGA International Growth I
TRVLX47.19N/A
N/A
T. Rowe Price Value
PHSKX59.97N/A
N/A
Virtus KAR Mid-Cap Growth A
JSMTX17.99N/A
N/A
Jackson Square SMID-Cap Growth Instl
JSLNX20.30-0.03
-0.15%
Janus Henderson Global Select N